Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - MESA LABORATORIES INC /CO/ex_188587.htm

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549   

 

FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

June 1, 2020
Date of Report (Date of earliest event reported)

 

MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

 

 

COLORADO
(State or other jurisdiction of
incorporation)

0-11740

(Commission File Number)

84-0872291
(I.R.S. Employer
Identification No.)

 

 

12100 WEST SIXTH AVENUE,

LAKEWOOD, COLORADO
(Address of principal executive offices)

 

80228
(Zip Code)

 

Registrant’s telephone number, including area code: (303) 987-8000

 

Not Applicable
(Former name or former address, if changed since last report)

 

Securities registered under Section 12(b) of the Act: 

Title of each class 

 

Trading Symbol

 

Name of each exchange on which

registered   

Common Stock, no par value

 

MLAB

 

The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 



 

 

 

ITEM 7.01    REGULATION FD DISCLOSURE.

 

In this Current Report on Form 8-K, we are furnishing a Power Point presentation that is scheduled to be used for an investor presentation on June 2, 2020. We expressly disclaim any obligation to update this presentation and caution that it is only accurate as of June 1, 2020. The inclusion of any data or statements in this presentation does not signify that the information is considered material. The presentation is also available at www.mesalabs.com, although the Company reserves the right to discontinue that availability at any time.

 

The information furnished in this Item 7.01, and Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act.

 

ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS

 

Exhibit No.

Description

99.1

Investor Presentation dated June 1, 2020

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

DATE: June 1, 2020

  

 

 

Mesa Laboratories, Inc.

 

 

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

 

 

 

BY: 

/s/ Gary M. Owens  

 

 

 

 

Gary M. Owens

 

 

 

 

President and Chief Executive Officer